CME webinar: ADHD Practice Guidelines

Dec. 2023Education/Webinars
Please join us for a live, CME-accredited webinar on Wednesday, April 17, from noon to 1 p.m. The webinar will provide an overview of ADHD practice guidelines and is being offered as part of the UPMC Health Plan Pediatric Collaborative Call series.

During this presentation, experts will discuss:
  • Familiarizing the prescriber with a variety of common problems and solutions in the diagnosis and treatment of ADHD in children and adolescents.
  • Information about the ADHD HEDIS® Quality Metrics.
  • Essential ADHD pharmacy related insights and the UPMC Health Plan resources to health care professionals engaged in prescribing ADHD medications.

Presenters:
  • Craig Coleman, MD, Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine; Attending Psychiatrist, UPMC Western Wellness, UPMC Behavioral Health of the Alleghenies, CCP Children’s TIPS
  • Debra Zeh, RN, BSN, Senior Director Quality Improvement, Provider Performance, UPMC Health Plan
  • Erin McConnell, PharmD, Senior Program Manager, Clinical Pharmacy, UPMC Health Plan

Register for the ADHD Practice Guidelines Webinar now. This webinar will be recorded.

You may earn continuing medical education (CME) credits for attending this webinar. This activity is approved for AMA PRA Category 1 Credit™, ANCC, ASWB, and ACPE. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

HEDIS® The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA.

Recent Announcements

Medicaid Renewal

Starting in 2027, some Medicaid recipients (ages 19–-64) will have new requirements to keep their coverage.
Aug. 2026Important Notices

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Aug. 2026Important Notices

Voluntary nationwide recall: Tyenne (Fresenius – August 2026)

Fresenius Kabi is recalling one lot, lot 16UI07, of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials. Tyenne is used for the treatment of certain arthritis conditions.
Aug. 2026Pharmacy Updates